Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy

Abstract Background Even though chemotherapy-induced nausea and vomiting (CINV) can be well controlled in the acute phase, the incidence of delayed CINV remains high. In this study, we intend to investigate whether prolonged use of NK-1 receptor antagonist (RA) in addition to 5-HT3 RA and dexamethas...

Full description

Bibliographic Details
Main Authors:	Ai Gao, Shasha Guan, Yinjuan Sun, Lingling Wang, Fanlu Meng, Xia Liu, Liyan Gu, Guo Li, Diansheng Zhong, Linlin Zhang
Format:	Article
Language:	English
Published:	BMC 2023-07-01
Series:	BMC Cancer
Subjects:	Prolonged Fosaprepitant Delayed CINV HEC
Online Access:	https://doi.org/10.1186/s12885-023-11070-3

Similar Items

A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
by: Koji Matsumoto, et al.
Published: (2020-05-01)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
by: Laurent Zelek, et al.
Published: (2023-08-01)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
by: Jianhua Chang, et al.
Published: (2020-07-01)

Effectivity of oral ginger supplementation for chemotherapy induced nausea and vomiting (CINV) in children: A systematic review of clinical trials
by: Harri Hardi, et al.
Published: (2024-07-01)

Curative Effect of Aprepitant Preventing CINV
by: Shasha GUAN, et al.
Published: (2018-10-01)

Fosaprepitant as combination therapy to prevent chemotherapy-induced vomiting in children: a meta-analysis
by: Yanshuo Shi, et al.
Published: (2025-01-01)

Prospective clinical evidence from over 1,000 pan-cancer patients: a complement to fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting
by: Lijuan He, et al.
Published: (2025-01-01)

Economic Value of Fosaprepitant-Containing Regimen in the Prevention of Chemotherapy-Induced Nausea and Vomiting in China: Cost-Effectiveness and Budget Impact Analysis
by: Xinglu Xu, et al.
Published: (2022-07-01)

Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial
by: Sukpiriyagul A, et al.
Published: (2023-08-01)

Efficacy of fosaprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery: a multicenter, randomized, double-blind study
by: Yingjun Zhang, et al.
Published: (2024-11-01)

Comparative Study Between Fosaprepitant and Palonosetron in the Prophylaxis of Postoperative Nausea and Vomiting in Women Undergoing Laparoscopic Cholecystectomy: Prospective, Randomized and Double-Blind Study
by: Estêvão Luiz Carvalho Braga, et al.
Published: (2022-05-01)

Chemotherapy induced nausea and vomiting may cause anxiety and depression in the family caregivers of patients with cancer
by: Xiaozhen Luo, et al.
Published: (2023-09-01)

The Influence of Hospital Service Standards on Quality of Life and Level Severity Chemotherapy Induces Nausea Vomiting (CINV) in Breast Cancer Patients
by: Siti Mu'awanah, et al.
Published: (2024-10-01)

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial
by: Schnadig ID, et al.
Published: (2017-05-01)

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin
by: Yuanyuan Zhao, et al.
Published: (2023-02-01)

Topical fosaprepitant for the treatment of ocular pain and inflammation
by: Giuseppe Suanno, et al.
Published: (2023-12-01)

Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: A randomized, open-label, phase 3 trial
by: Yi Cheng, et al.
Published: (2022-07-01)

Bibliometric and visual analysis of chemotherapy-induced nausea and vomiting (2004-2023)
by: Shao-Chuang Tian, et al.
Published: (2024-04-01)

Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug
by: Xiao-Ling Zhang, et al.
Published: (2022-10-01)

Advancements in managing chemotherapy-induced nausea and vomiting: From efficacy to cost-effectiveness
by: Yuvashree Chandrasekaran, et al.
Published: (2024-06-01)

Olanzapine enhances the effect of conventional drugs in chemotherapy induced nausea and vomiting: A randomized clinical trial
by: Atefe Khani, et al.
Published: (2022-02-01)

A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
by: Yilan Jin, et al.
Published: (2023-11-01)

Therapeutic study of the nausea and vomiting caused by chemotherapy medications by olanzapine to triple antiemetic therapy in Iraqi cancer patients
by: Ghufran salah ahmed, et al.
Published: (2023-05-01)

Patient-Related Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review
by: Abu Saleh Mohammad Mosa, et al.
Published: (2020-04-01)

Combination of thalidomide and Clostridium butyricum relieves chemotherapy-induced nausea and vomiting via gut microbiota and vagus nerve activity modulation
by: Xuanqi Zhao, et al.
Published: (2023-06-01)

A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II)
by: Kenichi Suzuki, et al.
Published: (2024-11-01)

Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
by: Soumya Simhadri, et al.

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
by: Lee Schwartzberg, et al.
Published: (2019-05-01)

The clinical effect of an electric massage chair on chemotherapy-induced nausea and vomiting in cancer patients: randomized phase II cross-over trial
by: Ju Won Kim, et al.
Published: (2024-04-01)

A deep learning‐based interpretable decision tool for predicting high risk of chemotherapy‐induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy
by: Jingyue Zhang, et al.
Published: (2023-09-01)

Effect of Persian Medicine Remedy on Chemotherapy Induced Nausea and Vomiting in Breast Cancer: A Double Blind, Randomized, Crossover Clinical Trial
by: Mohammad Nazari, et al.
Published: (2017-01-01)

Application of nurse‐led CINV management scheme based on risk assessment in breast cancer patients
by: Yun Ning, et al.
Published: (2024-12-01)

The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy
by: Aziz Eghbali, et al.
Published: (2023-01-01)

A prospective, pilot study on the use of olanzapine for optimum control of chemotherapy induced nausea and vomiting (CINV) in children with solid tumours receiving moderate/highly emetogenic chemotherapy at Tata Medical Center, Kolkata
by: Samik Samaddar, et al.
Published: (2017-01-01)

Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
by: Celio L, et al.
Published: (2013-05-01)

Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study
by: Takashi Yokokawa, et al.
Published: (2023-09-01)

Gambaran Skor INVR (Index of Nausea, Vomiting and Retching) pada CINV (Chemotherapy Induced Nausea and Vomiting) Kanker Payudara di RSUP M Djamil Padang
by: Wella Juartika, et al.
Published: (2020-01-01)

Risk Factors of Prolonged Nausea and Vomiting During Pregnancy
by: Zhang H, et al.
Published: (2020-11-01)

5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
by: Reiko Matsui, et al.
Published: (2020-10-01)

The use of aprepitant in the first cycle of moderately emetogenic chemotherapy in patients with colorectal cancer: its preventive effect on chemotherapy-induced nausea and vomiting
by: Jung Won Ryu, et al.
Published: (2013-06-01)